Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
about
Akt and mTOR in B Cell Activation and DifferentiationPharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemiaFocus on PTEN RegulationThe B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignanciesKilling me softly--future challenges in apoptosis researchThe tandem PH domain-containing protein 2 (TAPP2) regulates chemokine-induced cytoskeletal reorganization and malignant B cell migrationDasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemiaStereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells.Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.B-cell receptor signaling as a driver of lymphoma development and evolution.Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatmentZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulationON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancerCell Trafficking in Chronic Lymphocytic LeukemiaThe phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.The B-cell receptor signaling pathway as a therapeutic target in CLL.Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metforminIntegrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemiaEffectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice.Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.The microenvironment in mature B-cell malignancies: a target for new treatment strategiesChemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis.CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets.Targeting the B cell receptor pathway in chronic lymphocytic leukemia.Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer.Role of mesenchymal stem cells in leukaemia: Dr. Jekyll or Mr. Hyde?B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
P2860
Q21131224-B06EFC1F-01A9-457A-9AE2-C346FB06CF29Q26779129-D2AE4878-3543-4906-9E38-7D69C6DDE60BQ26797287-F3D9CAB6-079F-4A95-BCC1-6B462D765928Q26822700-C1B1DB63-D33A-4BC8-85E4-6C4DDD56F458Q27025213-11B447AC-8643-4C06-A580-83F7C28177D8Q27312363-9CB410BB-B80D-4CF2-988E-38E3D165A9AAQ28484839-F43D8126-C389-4F4E-A9E5-F8DFA447DC3FQ30365752-DF2637A3-C5FA-40C6-8D0C-FCB08687EFE6Q30994095-E83ABC4A-4E79-4A05-9A8A-26891245FF76Q33559560-081724A4-63D6-4187-BA28-DEC8C016249AQ34026194-A8DEC3D6-DC54-4DEF-A13D-9DDBD66576DFQ34042407-D24BAAD0-49AD-49D0-B616-99995E417120Q34081881-D5EC3E0C-9943-45C9-B1CA-CEDE876676C9Q34184717-2CB4B373-299E-4DA2-B8BC-06F6DEAA09BBQ34287781-45C15709-F6C7-456D-B425-5F0C32B331A5Q34398579-F1B5ED72-7BEE-423F-9DED-29B54FEDDF8EQ34508976-654EADD3-065C-4E19-9BBA-717C93EC9F15Q35061209-17E0C65B-5EDC-4831-AD9A-918F7349CDBBQ35875424-3F487E70-8DBA-407B-8C7F-17D4C98570DAQ35928964-747C4A57-7609-4E73-8E4D-89E9CD6BE966Q36115034-668E731C-B92F-42C7-B7FA-CDF06B2AC3A5Q36150234-8014AD66-5873-441A-B8F1-A790E353E4A1Q36163034-5C9BE340-0F74-4D9E-B885-6664A2BE7C46Q36462375-63ADA832-7633-4B69-A63D-86BB9C37FFE8Q36557448-39403307-4519-4836-8514-8E1128CFE8F5Q36737287-1EBCCDB6-718A-4BCC-A388-12602D323964Q36815262-2FB72110-1DE3-4FC3-A204-9D6C73B9BD0EQ36905125-4BF9E94B-15C1-4E5C-BF41-B9F887A85A6EQ37037294-47725080-5698-4101-80E4-AE351CC9F6F6Q37099769-0F646668-3508-4616-A46B-C553482BFBB1Q37305627-A2BF583F-5077-42CE-BDB3-DC22828C93C3Q37563816-4E653FA5-95A2-44ED-9B46-C68E7F3C6362Q37573641-E65382E1-14D5-444E-BE60-10C33DED5F6DQ37625487-560F8130-F13D-48DC-8F30-CA3748F3AEB4Q37866334-7ADA4326-E7C4-4CEA-9AAB-E1AD19307796Q38012179-D9A7A7A2-2777-410E-83BD-4427D3D4B32AQ38027501-14161288-B742-4F8A-AE6E-84244DB3A208Q38116454-6C06552F-2430-49CA-9858-F47F475CBA96Q38124120-9F93BD3F-828C-491E-8EA6-FCCA69FA9163Q38193070-B8C68C63-5725-4EB6-B98A-6C35E024B3F8
P2860
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Isoform-selective phosphoinosi ...... a novel therapeutic approach.
@en
Isoform-selective phosphoinosi ...... a novel therapeutic approach.
@nl
type
label
Isoform-selective phosphoinosi ...... a novel therapeutic approach.
@en
Isoform-selective phosphoinosi ...... a novel therapeutic approach.
@nl
prefLabel
Isoform-selective phosphoinosi ...... a novel therapeutic approach.
@en
Isoform-selective phosphoinosi ...... a novel therapeutic approach.
@nl
P2093
P2860
P50
P1433
P1476
Isoform-selective phosphoinosi ...... a novel therapeutic approach.
@en
P2093
Antonina V Kurtova
Bryan T Hennessy
Jan A Burger
Jianhua Hu
Kevan M Shokat
Marina Henneberg
Matthias Niedermeier
P2860
P304
P356
10.1182/BLOOD-2008-06-165068
P407
P577
2009-03-24T00:00:00Z